Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Anaplastic Lymphoma Kinase
100%
Alectinib
100%
Gilteritinib
100%
Human Lung Cancer Cell Line
20%
Natural Killer Cells
20%
Cell Proliferation
20%
Interleukin-15 (IL-15)
20%
Transition Factors
20%
Immunohistochemistry
10%
Attenuation
10%
Cancer Xenograft
10%
Clinical Trials
10%
Proliferation Apoptosis
10%
Immunoblotting
10%
MRNA Level
10%
Tumor
10%
Infiltration
10%
Tyrosine Kinase
10%
Non-small Cell Lung Cancer Cells
10%
Cell Infiltration
10%
Acquired Resistance
10%
Apoptosis Resistance
10%
Resistance Response
10%
Antitumor Efficacy
10%
Drug Tolerance
10%
FMS-like Tyrosine Kinase 3 (FLT3)
10%
Acute Myeloid Leukemia
10%
Anti-tumor Response
10%
Anticancer
10%
ALK Inhibitor
10%
Downstream Effectors
10%
Xenograft Tumor Model
10%
Xenograft Tumor
10%
Activity Range
10%
Multi-targeted Tyrosine Kinase Inhibitors
10%
Mouse Xenograft
10%
Proliferation Resistance
10%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Anaplastic Lymphoma Kinase
100%
Alectinib
100%
Gilteritinib
100%
Neoplasm
20%
Interleukin 15
20%
Mouse
10%
Clinical Trial
10%
Western Blot
10%
Protein Tyrosine Kinase
10%
Protein Tyrosine Kinase Inhibitor
10%
Drug Tolerability
10%
Acute Myeloid Leukemia
10%
Tumor Model
10%
Anaplastic Lymphoma Kinase Inhibitor
10%
Biochemistry, Genetics and Molecular Biology
Interleukin 15
20%
Drug Tolerance
10%